ES2080331T3 - Tratamiento de la obesidad con un agonista alfa-2-adrenergico y un peptido liberador de la hormona del crecimiento. - Google Patents

Tratamiento de la obesidad con un agonista alfa-2-adrenergico y un peptido liberador de la hormona del crecimiento.

Info

Publication number
ES2080331T3
ES2080331T3 ES91914999T ES91914999T ES2080331T3 ES 2080331 T3 ES2080331 T3 ES 2080331T3 ES 91914999 T ES91914999 T ES 91914999T ES 91914999 T ES91914999 T ES 91914999T ES 2080331 T3 ES2080331 T3 ES 2080331T3
Authority
ES
Spain
Prior art keywords
growth hormone
alpha
adrenergic agonist
obesity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91914999T
Other languages
English (en)
Inventor
Jesus Devesa Chalet As Mugica
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2080331T3 publication Critical patent/ES2080331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LOS PACIENTES DE OBESIDAD PUEDEN SER TRATADOS EFICAZMENTE AL ADMINISTRALES CONJUNTAMENTE UN AGONISTA ALFA-2-ADRENERGICO, TAL COMO CLONIDINA, Y UN PEPTIDO DE LIBERACION DE HORMONA DE CRECIMIENTO, TAL COMO GHRH, PARA RESTABLECER O REALZAR SUSTANCIALMENTE LA LIBERACION DE LA HORMONA DEL CRECIMIENTO EN DICHOS PACIENTES.
ES91914999T 1990-09-10 1991-09-06 Tratamiento de la obesidad con un agonista alfa-2-adrenergico y un peptido liberador de la hormona del crecimiento. Expired - Lifetime ES2080331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/580,686 US5120713A (en) 1990-09-10 1990-09-10 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide

Publications (1)

Publication Number Publication Date
ES2080331T3 true ES2080331T3 (es) 1996-02-01

Family

ID=24322121

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91914999T Expired - Lifetime ES2080331T3 (es) 1990-09-10 1991-09-06 Tratamiento de la obesidad con un agonista alfa-2-adrenergico y un peptido liberador de la hormona del crecimiento.

Country Status (11)

Country Link
US (1) US5120713A (es)
EP (1) EP0500847B1 (es)
JP (1) JP3255289B2 (es)
AT (1) ATE131063T1 (es)
AU (1) AU650048B2 (es)
CA (1) CA2072624C (es)
DE (1) DE69115247T2 (es)
DK (1) DK0500847T3 (es)
ES (1) ES2080331T3 (es)
GR (1) GR3018922T3 (es)
WO (1) WO1992004040A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US7077822B1 (en) 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US6231594B1 (en) 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
EP1353695A2 (en) * 2001-01-26 2003-10-22 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CN101785772A (zh) * 2001-09-21 2010-07-28 先灵公司 使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
JP2006508188A (ja) * 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
EP2185182A1 (en) * 2007-09-11 2010-05-19 Mondobiotech Laboratories AG Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IT1191611B (it) * 1985-05-15 1988-03-23 Eugenio E Muller Formalazioni farmaceutiche per stimolare la liberazione di ormone somatotropo
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative

Also Published As

Publication number Publication date
JPH05503710A (ja) 1993-06-17
JP3255289B2 (ja) 2002-02-12
AU8430591A (en) 1992-03-30
DE69115247D1 (de) 1996-01-18
CA2072624C (en) 1999-03-23
WO1992004040A1 (en) 1992-03-19
AU650048B2 (en) 1994-06-09
EP0500847A1 (en) 1992-09-02
CA2072624A1 (en) 1992-03-11
US5120713A (en) 1992-06-09
DE69115247T2 (de) 1996-07-25
EP0500847B1 (en) 1995-12-06
DK0500847T3 (da) 1996-01-08
ATE131063T1 (de) 1995-12-15
GR3018922T3 (en) 1996-05-31

Similar Documents

Publication Publication Date Title
GR3018922T3 (en) Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide.
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
ES2154299T3 (es) Metodos para la regulacion de la motilidad gastrointestinal.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
DK0415613T3 (da) Anvendelse af sertralin til behandling af præmatur ejakulation
MY106075A (en) A method of treating anxiety-related disorders using sertraline.
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
RU2000100346A (ru) Способы лечения ожирения
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
ES2084057T3 (es) Bacterina para el tratamiento de enfermedades causadas por f. necrophorum y procedimiento para su produccion.
ES2090137T3 (es) Procedimiento para tratar la infertilidad y agente para utilizar en el procedimiento.
KR920700029A (ko) 상피소체 고혈압성 인자(parathyroid hypertensive factor)
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
ATA22989A (de) Behandlungsliege, insbesondere massageliege
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
BG49742A1 (en) Affrodisiance means
EP1328273A4 (en) ADDITIVES AND METHODS FOR THE TRANSDERMAL APPLICATION OF FELODIPIN
MXPA94001379A (es) Tratamiento selectivo de infecciones causadas por enterovirus en seres humanos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 500847

Country of ref document: ES